Bovine herpesvirus 5

Lore & Background

Bovine herpesvirus 5 is a member of the genus Varicellovirus and subfamily Alphaherpesvirinae. It primarily causes meningoencephalitis and respiratory disease in cattle and sheep. Like other herpesviruses, it can establish latent infection, with reactivation occurring during periods of stress or immunosuppression. Latency sites include the central nervous system and the mucosae of the nose and trachea. The disease has been reported in South America, the United States, Australia, Germany, and Hungary, and is most common in calves up to ten months of age.

Clinical signs of respiratory disease include tachycardia, tachypnea, pyrexia, dyspnea, mucoid nasal discharge, hypersalivation, and abnormal lung sounds, along with systemic signs such as lethargy and anorexia. Neurological signs are typically acute and include opisthotonus, hyperaesthesia, abnormal behavior, ataxia, head pressing, blindness, proprioceptive deficits, coma, and seizures. Sudden death can occur in neonates, and subacute disease is almost always fatal, presenting with depression, anorexia, ataxia, and pronounced dyspnea.

Diagnosis is made by identifying the virus using specific monoclonal antibodies, PCR, or ELISA. Neurological lesions should be identifiable on postmortem examination. There is currently no specific treatment or vaccine for BoHV-5, though Bovine herpesvirus 1 vaccines appear to provide some cross-protection.

Reader's Guide

Bovine herpesvirus 5 is significant as a pathogen of cattle and sheep, causing both respiratory disease and often fatal meningoencephalitis, particularly in young calves. Its ability to establish latency in the central nervous system and respiratory mucosae, with reactivation under stress, complicates control efforts. The virus has a documented presence in multiple continents, including South America, North America, Australia, and Europe. Diagnosis relies on molecular and serological methods, and while no specific vaccine exists, cross-protection from Bovine herpesvirus 1 vaccines offers a partial management tool. The high fatality rate of subacute neurological disease and sudden death in neonates underscores its economic and animal welfare impact. Understanding its latency and recrudescence mechanisms remains important for developing future interventions.

Did You Know?

• Bovine herpesvirus 5 causes meningoencephalitis and respiratory disease in both cattle and sheep.
• Latent infection can occur, with recrudescence during times of stress or immunosuppression.
• The disease is most common in calves up to ten months of age.
• There is no specific treatment or vaccine for Bovine herpesvirus 5, but Bovine herpesvirus 1 vaccines provide some cross-protection.

Taxonomic Classification and Viral Biology

Bovine herpesvirus 5 belongs to the genus Varicellovirus within the subfamily Alphaherpesvirinae, placing it among a group of viruses well known for their capacity to establish long-term, dormant infections in their hosts. Unlike many pathogens that are cleared after an acute episode, BoHV-5 can persist in the body indefinitely. Once the initial infection subsides, the virus retreats into latent reservoirs—specifically the central nervous system and the mucosal linings of the nasal passages and trachea. From these hiding places, the virus can reactivate, a process termed recrudescence, typically triggered by periods of physiological stress or when the host's immune defenses are weakened. This latent capacity means that an animal which has recovered from a bout of BoHV-5 disease, or one that becomes secondarily infected following a Bovine herpesvirus 1 episode, may carry the virus silently for the rest of its life, serving as a potential source of reinfection or transmission. The virus targets both cattle and sheep, where it is responsible for two major disease manifestations: meningoencephalitis affecting the brain and its surrounding membranes, and respiratory tract disease.

Clinical Presentation and Disease Progression

The clinical picture of BoHV-5 infection unfolds across two primary organ systems. Respiratory manifestations present with elevated heart rate and breathing frequency, fever, labored breathing, thick mucus discharge from the nostrils, excessive salivation, and irregular sounds heard over the lungs. Systemic indicators such as marked lethargy and loss of appetite often accompany these pulmonary signs. The neurological dimension tends to strike suddenly and severely. Affected animals may exhibit opisthotonus—a rigid arching of the back—along with heightened sensitivity to stimuli, erratic behavior, uncoordinated movement, pressing of the head against objects, loss of vision, impaired sense of limb position, progression to coma, and full seizures. In the most vulnerable group, neonatal calves, the disease can culminate in sudden death without warning. When the illness follows a subacute course, the prognosis is grim: the condition is almost invariably fatal, marked by progressive depression, refusal to eat, a staggering gait, and increasingly severe difficulty breathing. Calves up to ten months of age represent the population most frequently affected by this virus.

Geographic Distribution and Host Susceptibility

Documented cases of Bovine herpesvirus 5 have been reported across a wide range of continents and climatic zones, confirming that the virus is not confined to a single region. Outbreaks and individual cases have been recorded in South America, the United States, Australia, Germany, and Hungary, illustrating its broad geographic footprint. Within affected herds, the virus shows a pronounced predilection for young animals. Calves up to ten months of age are the group most commonly struck, suggesting that the developing immune systems of neonates and young calves leave them particularly vulnerable to both the respiratory and neurological forms of the disease. This age-related susceptibility pattern is clinically significant because it concentrates the economic and welfare impact on the youngest segment of a breeding operation. Furthermore, the virus does not discriminate strictly by species; both cattle and sheep are susceptible hosts, broadening the range of livestock operations that must consider BoHV-5 in their disease surveillance. The fact that recovered animals can become long-term latent carriers adds another layer of complexity, as seemingly healthy stock may harbor the virus and potentially shed it under conditions of stress or immunosuppression, perpetuating the cycle of infection within and between herds.

Diagnostic Approaches and Management Limitations

Confirming a BoHV-5 infection relies on a combination of laboratory and postmortem tools. In live or recently deceased animals, the virus can be identified through the use of specific monoclonal antibodies that recognize viral proteins, through polymerase chain reaction assays that detect viral genetic material, or through enzyme-linked immunosorbent assays that measure immune responses. When animals die, examination of the central nervous system at postmortem can reveal characteristic neurological lesions that support the diagnosis. On the therapeutic front, however, the situation remains unsatisfying. As of the available literature, there is no approved antiviral treatment specifically designed for BoHV-5, nor is there a dedicated vaccine targeting this particular virus. The closest available prophylactic measure is the use of Bovine herpesvirus 1 vaccines, which appear to confer a degree of cross-protection against BoHV-5, though this is not a substitute for a virus-specific immunization strategy. This gap in treatment and prevention means that management of BoHV-5 outbreaks depends heavily on early diagnosis, isolation of affected animals, and supportive care, while long-term control rests on the partial shield offered by cross-reactive BoHV-1 vaccination.